Linesight’s client is building a new facility dedicated to the development and manufacturing of viral vectors. The new facility will be constructed within an existing biologics operations facility and will help build on our confidential client’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer.
The new facility will be approximately 67,000 sq. ft. and consist of two multi-product viral vector manufacturing suites, two cell expansion suites, two filling suites, as well as warehousing, shipping and receiving, final product storage, working cell bank storage, quality control laboratories, and office and support areas for employees.